Skip to main content
SpringerLink
Log in

Potent Gastric Acid Inhibition in the Management of Barrett’s Oesophagus

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Barrett’s oesophagus is the consequence of excessive and prolonged gastrooesophageal reflux. The therapeutic objectives in Barrett’s oesophagus include the reduction of gastro-oesophageal reflux in order to relieve symptoms and the prevention of the biologic progression to adenocarcinoma. The first objective may be achieved with standard proton pump inhibitor (PPI) therapy, which is the base of the medical therapy in this type of patients, but this therapy has been found not to be associated with normalization of the intraluminal pH of the oesophagus in many patients with Barrett’s oesophagus. This condition seems to be necessary in order to reduce mucosal cell proliferation in some studies. Therefore, it has been proposed that patients with Barrett’s oesophagus need profound acid inhibition with high-dose PPI. This therapeutic approach provides symptom relief, but there is no direct evidence that it is associated with Barrett’s oesophagus regression or progression to adenocarcinoma. Nevertheless, recent and preliminary data suggest that long-term PPI therapy may reduce the risk of developing disease progression. Profound acid inhibition is also combined with endoscopy ablative or resection therapy in patients with Barrett’s oesophagus. This therapeutic approach should be still regarded as experimental and more data are needed before its therapeutic role in patients with Barrett’s oesophagus is established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Spechler SJ. Barrett’s esophagus. N Engl J Med 2002; 346: 836–42

    Article  PubMed  Google Scholar 

  2. Alcedo J, Lanas A, Ferrandez A, et al. Trends in the epidemiology and outcome of Barrett’s esophagus in Spain. Gut 2002; 51 Suppl 3: A27

    Google Scholar 

  3. Morales C, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet 2002; 360: 1587–9

    Article  PubMed  Google Scholar 

  4. Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2002; 97: 1888–95

    Article  PubMed  Google Scholar 

  5. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 2004; 99: 991–6

    Article  PubMed  Google Scholar 

  6. Basu KK, Bale R, West KP, et al. Persistent acid reflux and symptoms in patients with Barrett’s oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1187–92

    Article  PubMed  CAS  Google Scholar 

  7. Sarela AI, Hick DG, Verbeke CS, et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esopha-gus receiving proton pump inhibitor therapy. Arch Surg 2004; 139: 547–51

    Article  PubMed  CAS  Google Scholar 

  8. Yeh RW, Gerson LB, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus 2003; 16: 193–8

    Article  PubMed  CAS  Google Scholar 

  9. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett’s esophagus. Am J Gastroenterol 1997; 92: 582–5

    PubMed  CAS  Google Scholar 

  10. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286–93

    Article  PubMed  CAS  Google Scholar 

  11. Csendes A. Surgical treatment of Barrett’s esophagus: 1980–2003. World J Surg 2004; 28: 225–31

    Article  PubMed  Google Scholar 

  12. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Standard antireflux operations in patients who have Barrett’s esophagus. Current results. Chest Surg Clin N Am 2002; 12: 113–26

    Article  PubMed  Google Scholar 

  13. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett’s oesophagus during omeprazole treat-ment; a randomised double blind study. Gut 1999; 45: 489–94

    Article  PubMed  CAS  Google Scholar 

  14. Neumann CS, Iqbal TH, Cooper BT. Long term continuous omeprazole treatment of patients with Barrett’s oesophagus. Aliment Pharmacol Ther 1995; 9: 451–4

    Article  PubMed  CAS  Google Scholar 

  15. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120–8

    CAS  Google Scholar 

  16. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett’s esophagus. Gastroenterology 2002; 122: 299–307

    Article  PubMed  CAS  Google Scholar 

  17. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327–35

    Article  PubMed  CAS  Google Scholar 

  18. Peters FT, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 2000; 35: 1238–44

    Article  PubMed  CAS  Google Scholar 

  19. Gurski RR, Peters JH, DeMeester SR, et al. Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003; 196: 706–12; discussion 712-13

    Article  PubMed  Google Scholar 

  20. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett’s oesophagus: long-term results of a prospective study. Br J Surg 1996; 83: 274–8

    Article  PubMed  CAS  Google Scholar 

  21. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8

    Article  PubMed  CAS  Google Scholar 

  22. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 2004; 180: 375–6

    Google Scholar 

  23. Lanas A. Nuevas perspectivas terapeuticas en el esófago de Barrett. Gastroenterol Hepatol 2003; 27: 21–9

    CAS  Google Scholar 

  24. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 950–5

    Article  PubMed  CAS  Google Scholar 

  25. Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 2002; 51: 776–80

    Article  PubMed  CAS  Google Scholar 

  26. Weston AP, Badr AS, Hassanein RS. Prospective multi-variate analysis of factors predictive of complete regres-sion of Barrett’s esophagus. Am J Gastroenterol 1999; 94: 3420–6

    Article  PubMed  CAS  Google Scholar 

  27. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747–51

    Article  PubMed  Google Scholar 

  28. Wurm P, de Caestecker J. Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett’s oesophagus. Expert Opin Pharmacother 2003; 4: 1049–61

    Article  PubMed  CAS  Google Scholar 

  29. Sneineh AA, Tam W, Schoeman M, et al. Magnitude of gastric and oesophageal acid control with Esomeprazole 40 mg bd in comparison with standard ppi in patients with Barrett’s oesophagus. Gut 2004; 53 Suppl VI: A102

    Google Scholar 

  30. Spechler S, Sharma P, Traxler B, et al. Effect of esomeprazole on intragastric and intraesophageal ph in patients with Barrett’s esophagus. Gastroenterology 2004; 126 Suppl 2: S1245

    Article  Google Scholar 

Download references

Acknowledgement

This manuscript was made possible by a grant from Astra Zeneca, Spain and grant C03/02 from the Instituto de Investigación Carlos III.

Author information

Authors and Affiliations

  1. Gastroenterology Service, Clinical University Hospital, 50009, Zaragoza, Spain

    Ángel Lanas

Authors
  1. Ángel Lanas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ángel Lanas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanas, Á. Potent Gastric Acid Inhibition in the Management of Barrett’s Oesophagus. Drugs 65 (Suppl 1), 75–82 (2005). https://doi.org/10.2165/00003495-200565001-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565001-00011

Keywords

Search

Navigation